foods glp-1 Best Frozen Meals for Users: A Protein-First Guide – Counter The GLP-1 Diet: How &

A looming issue therefore for payers and patients will be pricing of the oral non-peptide GLP-1 orforglipron

The DAFNE programme assists them to identify their own individual dose requirements, and thus a proportion of DAFNE participants lose weight following the programme

Jeyakumar Y, Richardson L, Sarma S, Retnakaran R, Kramer CK

Biopharma companies face: Massive competition and potential market saturation with over 500 GLP-1-related clinical trials across 100+ indications Downward price pressure Highly restricted reimbursement and resistance to new indications Mechanism-based stratification can: Enrich clinical trials for responders (response biomarkers) Identify strong responder subgroups (complementary diagnostic) Differentiate competing assets Support development in new indications (biomarker-led indication switching) De-risk late-stage programs (clinical trial design) Past efforts to expand GLP-1s into new indications - such as the semaglutide Alzheimers trial - largely targeted broad patient groups defined by their clinical symptoms or diagnostic labels

Please see Saxenda Instructions for Use for more information

Suggested use: 46 weeks per course, followed by a 2-week break